Pharmaceutical

Angle signs AstraZeneca deal to develop prostate cancer assay

UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.

May 5, 2024 - 00:00
Angle signs AstraZeneca deal to develop prostate cancer assay
UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.
Read the original article

Tags:

Previous Article

SCAI names James B. Hermiller, MD, MSCAI, President for 2024-25

Next Article

FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Likelihood of Approval

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Li...

Nov 2, 2023

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn

Lantheus acquires radiopharma CDMO Evergreen for up to ...

Jan 30, 2025

FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date

FDA will not meet ahead of bluebird bio’s sickle cell d...

Aug 16, 2023